作为二线疗法,尼沃卢马布改善了无法切除的肝细胞癌患者的存活率
Faisal M Sanai1,2,3, Hassan O Odah1, Kanan Alshammari4
1Gastroenterology Section, Department of Medicine, King Abdulaziz Medical City, Ministry of the National Guard-Health Affairs, Jeddah 21423, Saudi Arabia.
Cancers
|June 27, 2024
概括
二线尼沃卢马布显著改善了无法切除的肝细胞癌 (uHCC) 患者的整体存活率,这些患者在索拉费尼布治疗中进展. 这些现实研究结果支持尼沃卢马布作为晚期肝癌的有效治疗选择.
科学领域:
- 肝胆道癌症 肝胆道癌症
- 医学瘤学 医学瘤学
- 免疫治疗是一种免疫疗法.
背景情况:
- 关于尼沃卢马布在不可切除的肝细胞癌 (uHCC) 的二线治疗中有效性的数据有限.
- 这项研究评估了nivolumab在HHCC患者的有效性,这些患者在索拉芬尼治疗后进展.
研究的目的:
- 评估二线尼沃卢马布在不可切除的肝细胞癌 (uHCC) 的疗效和安全性.
- 为了比较接受尼沃卢马布和继续接受索拉芬尼布的患者之间的整体存活期 (OS).
主要方法:
- 对42名接受二线尼沃卢马布治疗的患者进行了回顾性,观察性,多中心的研究,与38名接受索拉芬尼布治疗的历史对照进行了对照.
- 主要终点:从索拉费尼布治疗开始的整体存活率 (OS),按治疗意图分析.
- 这些患者患有无法切除的肝细胞癌 (uHCC),并且在sorafenib治疗中进展.
主要成果:
- 治疗二线尼沃卢马布的中位寿命为22.2个月,仅治疗索拉费尼布的中位寿命为11.0个月 (HR1.93,p=0.014).
- 尼沃卢马布组有更多的并发病,更高的ECOG-2状态,BCLC阶段C和外血管入侵.
- 开始服用尼沃卢马布后的中位 OS 为 10.2 个月;进展时间为 4.9 个月.
结论:
- 尼沃卢马布证明了作为二线治疗索拉费尼布后不可切除的肝细胞癌 (uHCC) 的显著整体生存益处.
- 现实世界的数据与之前的临床试验结果一致,支持nivolumab的疗效.
- 在这种患者群体中,需要对尼沃卢马布单一治疗进行进一步的研究.
相关概念视频
01:27Tumor Immunotherapy
510
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
510
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:30Cancer Vaccines
351
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
351